Integrated Biotherapeutics, Inc.

Integrated Biotherapeutic Vaccines, Inc.

US Government As Represented by the Secretary of the Army

Leland Stanford Junior University

University System of Maryland

Integral Molecular, Inc.

Abvacc, Inc.

Razi Holdings, Inc.

Mohammad Javad Aman

Rajan Prasad Adhikari

Hatice Karauzum

Frederick Wayne Holtsberg

Kelly Lyn Warfield

Thomas Kort

Nils Williston

Katie A Howell

Sergey Shulenin

Tam Nguyen

Arundhathi Venkatasubramaniam

Frederick W Holtsberg

Sina Bavari

Yuxing Li

Benjamin J Doranz

Zhen-Yong Keck

James C Burnett

Steven K H Foung

Sven G Enterlein

Edgar Davidson

Jawad Sarwar

Sathya Venkataramani

Xuelian Zhao

Shweta Kailasan

Tam Luong Nguyen

The present disclosure provides immunogenic compositions useful in prevention and treatment ofinfection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.

Immunogenic composition comprising a fusion peptide derived from superantigen toxoids

The present disclosure provides immunogenic compositions useful in prevention and treatment ofinfection. In particular, the disclosure provides methods of inducing an immune response against a LukAB-expressingmethods of preventing or treatinginfections, and composition for preventing or treatinginfections.

[object Object]

This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.

Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop

Provided herein are methods of incorporating substitutions of specified residues into a filovirus GP in order to increase immunogenicity and/or broaden the cross-reactivity of the protective immune response against other filovirus members. Also provided herein are mutant filovirus GPs comprising such substitutions.

Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity

This disclosure provides a comprehensive approach to specifically target various immune functions to the site of infection by a variety of fusion proteins that consist of a bacteriolysin cell wall targeting domain (CWT) and an immune function mediating component (IFMC). The CWT targets the fusion protein to the bacterial surface leading to accumulation at the site of infection. The IFMC mediates various immune functions such as toxin neutralization or recruitment of immune cells that can clear the bacteria.

Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins

The disclosure provides non-human primate-derived binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.

Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins

This disclosure provides a comprehensive approach to specifically target various immune functions to the site of infection by a variety of fusion proteins that consist of a bacteriocin cell wall targeting domain (CWT) and an immune function mediating component (IFMC). The CWT targets the fusion protein to the bacterial surface leading to accumulation at the site of infection. The IFMC mediates various immune functions such as toxin neutralization or recruitment of immune cells that can clear the bacteria.

The present disclosure provides immunogenic compositions useful in prevention and treatment ofinfection. In particular, the disclosure provides delta toxin and phenol-soluble modulin peptides as well as mutants, fragments, variants or derivatives thereof. The disclosure further provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal proteins, e.g., DT, PSM, alpha hemolysin, leukocidin, superantigen, or any fragments, variants, derivatives, or mutants thereof fused together as a single polypeptide in any order.

Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

The present disclosure provides immunogenic compositions useful in prevention and treatment ofinfection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing, methods of preventing or treatinginfections, and composition for preventing or treatinginfections.

Immunogenic composition comprising Panton-Valentine Leukocidin (PVL) derived polypeptides

The present invention provides immunogenic compositions useful in prevention and treatment ofinfection. In particular, the present invention provides methods of inducing an immune response against an alpha-hemolysin-expressing, methods of preventing or treatinginfections, and composition for preventing or treatinginfections.

Immunogenic composition comprising alpha-hemolysin oligopeptides

Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.

Growing community of inventors

Rockville, MD, United States of America

Mohammad Javad Aman